Intelligent Ultrasound Group plc

AIM:IUG Stock Report

Market Cap: UK£37.6m

Intelligent Ultrasound Group Valuation

Is IUG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IUG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IUG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IUG's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IUG?

Key metric: As IUG is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IUG. This is calculated by dividing IUG's market cap by their current revenue.
What is IUG's PS Ratio?
PS Ratio3.8x
SalesUK£9.88m
Market CapUK£37.63m

Price to Sales Ratio vs Peers

How does IUG's PS Ratio compare to its peers?

The above table shows the PS ratio for IUG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.3x
RENX Renalytix
14.2x108.3%UK£25.7m
COG Cambridge Cognition Holdings
0.9x11.0%UK£11.9m
OPT Optima Health
1.3x1.7%UK£143.8m
INHC Induction Healthcare Group
0.7x13.0%UK£8.4m
IUG Intelligent Ultrasound Group
3.8xn/aUK£37.6m

Price-To-Sales vs Peers: IUG is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does IUG's PS Ratio compare vs other companies in the European Healthcare Services Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
IUG 3.8xIndustry Avg. 2.3xNo. of Companies10PS02.44.87.29.612+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IUG is expensive based on its Price-To-Sales Ratio (3.8x) compared to the European Healthcare Services industry average (2.3x).

Price to Sales Ratio vs Fair Ratio

What is IUG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IUG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IUG's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.05

7D

-4.2%

1Y

4.8%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.52

7D

-5.4%

1Y

-8.8%

Guerbet

€335.4m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€26.70

7D

-9.6%

1Y

50.0%